Patents Assigned to Merck
  • Anti-TIGIT antibodies
    Patent number: 12102680
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: October 1, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
  • Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
    Patent number: 12103930
    Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: October 1, 2024
    Assignee: MERCK & CIE
    Inventors: Rudolf Moser, Viola Groehn, Thomas Egger, Thomas Ammann
  • Liquid-crystal medium
    Patent number: 12104109
    Abstract: A liquid-crystal (LC) material having negative dielectric anisotropy and the use thereof for optical, electro-optical and electronic purposes, such as for example in LC displays, in particular energy saving displays based on the ECB, IPS or FFS effect, where the liquid crystal medium contains one or more compounds of formula I and one or more compounds compounds of formulae IIA, IIB, IIC and IID
    Type: Grant
    Filed: June 22, 2023
    Date of Patent: October 1, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Chi-Shun Huang, Sven Christian Laut, Hee-Kyu Lee, Minghui Yang, Harald Hirschmann, Kuang-Ting Chou, Shih-Chieh Hung, Alexander Hahn, Philipp Wucher
  • Tricyclic heterocycles
    Publication number: 20240317753
    Abstract: Tricyclic heterocycles are disclosed. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.
    Type: Application
    Filed: May 5, 2021
    Publication date: September 26, 2024
    Applicants: Merck Patent GmbH, Cancer Research Technology Ltd.
    Inventors: Timo HEINRICH, Sarah Schlesiger, Jakub Gunera, Emma Carswell, Lisa Koetzner, Andreas Blum
  • METHODS FOR TREATING CANCER WITH ANTI-ILT3 ANTIBODIES
    Publication number: 20240317854
    Abstract: This disclosure relates to methods for treating solid tumors in a patient identified as having metastatic triple negative breast cancer, glioblastoma, metastatic pancreatic ductal adenocarcinoma, metastatic soft tissue sarcoma, or metastatic non-squamous non-small cell lung carcinoma, comprising administering an anti-ILT3 antigen binding protein, or antigen binding fragment, and an anti-PD1 antigen binding protein, or antigen binding fragment, to the patient every three weeks (Q3W).
    Type: Application
    Filed: March 17, 2022
    Publication date: September 26, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Philip E. Brandish, Mei Chen, Andrey Loboda, Michael Nebozhyn, III, Cai Wu, Daping Zhang, Jie Zhang-Hoover
  • Rinse and method of use thereof for removing edge protection layers and residual metal hardmask components
    Patent number: 12099305
    Abstract: The disclosed subject matter relates to a rinse and methods of use thereof for removing an edge protection layer and residual hardmask components (e.g., metals) from the edge and at least one proximate surface of a wafer/substrate where the rinse includes acetic acid and/or a halogenated acetic acid of structure (A) wherein R1 and R2 are independently hydrogen or a halogen and R3 is a halogen and (ii) a compound having structure (B) wherein each of Ra, Rb, Rc, Rd, Re, Rf, Rg and Rh may independently be hydrogen, a substituted or an unsubstituted alkyl group, a substituted or an unsubstituted halogenated alkyl group, a substituted or an unsubstituted alkyl carbonyl group, a halogen, and a hydroxy group.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: September 24, 2024
    Assignee: Merck Patent GmbH
    Inventors: M. Dalil Rahman, Salem Mullen, JoonYeon Cho
  • Compositions comprising polysaccharide-protein conjugates and methods of use thereof
    Patent number: 12097250
    Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
    Type: Grant
    Filed: November 9, 2023
    Date of Patent: September 24, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski
  • IL-2 MUTEINS FOR TREATING CANCER OR INFECTION
    Publication number: 20240309061
    Abstract: Provided herein are IL-2 muteins that bind to the IL-2 receptor ? subunit but do not have measurable binding to the IL-2 receptor a subunit. Also provided are compositions, kits, methods, and uses involving such IL-2 muteins.
    Type: Application
    Filed: July 21, 2022
    Publication date: September 19, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Juan C. Alvarez, Alan C. Cheng, Ghassan N. Fayad, Brian E. Hall, Veronica M. Juan, Peter S. Kim, Sheila H. Ranganath, Venkataraman Sriraman, Gary C. Starling, Nicole C. Walsh
  • HETEROARYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20240308980
    Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 19, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kaleen Konrad Childers, J. Michael Ellis, Peter H. Fuller, Anmol Gulati, Hakan Gunaydin, Solomon D. Kattar, Ravi Kurukulasuriya, Joey L. Methot, Gregori J. Morriello, Santhosh Neelamkavil, Blair T. Lapointe, Vladimir Simov, Charles S. Yeung
  • Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 12091405
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 17, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Dane Clausen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, David Sloman, Li Xiao, Wensheng Yu, Rui Zhang
  • ENZYMATIC SYNTHESIS OF 4'-ETHYNYL NUCLEOSIDE ANALOGS
    Publication number: 20240301460
    Abstract: The present invention relates to an enzymatic synthesis of 4?-ethynyl-2?-deoxy nucleosides and analogs thereof, for example EFdA, that eliminates the use of protecting groups on the intermediates, improves the stereoselectivity of glycosylation and reduces the number of process steps needed to make said compounds. It also relates to the novel intermediates employed in the process.
    Type: Application
    Filed: May 28, 2024
    Publication date: September 12, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Mark A. Huffman, Anna Fryszkowska, Joshua N. Kolev, Paul N. Devine, Kevin R. Campos, Matthew Truppo, Christopher C. Nawrat
  • ANTI-FOLR1 IMMUNOCONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS
    Publication number: 20240299571
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-PD-1 antibodies or antigen-binding fragments thereof (e.g., pembrolizumab) are provided. Methods of administering the combinations to treat cancers, e.g., ovarian, peritoneal, or fallopian tube cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Application
    Filed: October 18, 2023
    Publication date: September 12, 2024
    Applicants: ImmunoGen, Inc., Merck Sharp & Dohme LLC
    Inventor: Rodrigo R. RUIZ SOTO
  • Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
    Patent number: 12083112
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: September 10, 2024
    Assignees: EISAI R&D MANAGEMENT CO., LTD., Merck Sharp & Dohme LLC
    Inventors: Andrew Evan Denker, Yu Kato, Kimiyo Tabata, Yusaku Hori
  • Surface display of whole antibodies in eukaryotes
    Patent number: 12084651
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: September 10, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • GCN2 inhibitors and uses thereof
    Patent number: 12084438
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: September 10, 2024
    Assignees: Merck Patent GmbH, Vertex Pharmaceuticals Incorporated
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • Mixing device
    Patent number: 12083486
    Abstract: A mixing device (1) for cyclically imparting a force on an external surface (A) of a bag (B) for agitating a content (C) of the bag (B), the mixing device (1) comprising a lever (2) supported so as to be able to pivot about a pivot (3), a weight (4) provided on a first side of the lever (2), a driver (5) arranged to cooperate with the lever (2), a motor (6) for moving the driver (5) to lift the first side of the lever (2) with the weight (4) against gravity and to drop the first side against the external surface (A) of the bag (B), and a holder (7) for supporting the mixing device (1) such that the first side of the lever (2) can contact the external surface (A) of the bag (B) in the drop motion.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: September 10, 2024
    Assignee: Merck Patent GmbH
    Inventors: Stephane Olivier, Gaetan Bour
  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20240294596
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: September 7, 2021
    Publication date: September 5, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Dmitri A. Pissarnitski, Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Ravi Nargund, Zhicai Shi, Zhicai Wu, Lin Yan, Yuping Zhu
  • Heteroaromatic isothiocyanates
    Patent number: 12077703
    Abstract: The present invention relates to heteroaromatic isothiocyanates of formula N as defined in claim 1, to liquid-crystalline media comprising one or more compounds of formula N and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: September 3, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Amir Hossain Parham, Constanze Brocke, Carsten Fritzsch, Dagmar Klass
  • Compounds for electronic devices
    Patent number: 12077541
    Abstract: The present application relates to an amine compound according to formula (I), (II) or (III) which is suitable for use in electronic devices.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: September 3, 2024
    Assignee: Merck Patent GmbH
    Inventors: Ilona Stengel, Florian Maier-Flaig, Philipp Harbach, Elvira Montenegro, Aurélie Ludemann
  • Tubing connectors
    Patent number: 12078273
    Abstract: The disclosure herein relates to a flow path comprising half clamps 1 having an interior surface surrounding a flexible tubing 3 connection with a barb adapter 3, when assembled may be placed within a clamshell reduce or prevent deformation of the flexible tubing.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: September 3, 2024
    Assignee: Merck Patent GmbH
    Inventors: Olivier Flick, Robert Langlois, James Vigna, Christine Crequy, Thomas Coton